Claim OwnershipBeyond Biotech - the podcast from Labiotech
Subscribed: 91Played: 1,496
Subscribe
© 2024 Beyond Biotech - the podcast from Labiotech
Description
Welcome to the official Labiotech.eu podcast - Beyond Biotech! Each week, we talk about what's happening in the world of biotech, with news and interviews with experts from companies around the world. Join us as we cover the latest news, breakthroughs and innovations shaping the life sciences industry.A new podcast episode is available every Friday.The host is Jim Cornall.
129 Episodes
Reverse
While our podcast takes a brief break, Labiotech invites you to enjoy some of our favorite episodes. We will return with a brand-new episode on January 3rd, 2025! Have an awesome holiday season!On this podcast, we speak to Artiva Biotherapeutics’ CEO, Fred Aslan, M.D.The company has demonstrated the potential for efficacy and safety with natural killer (NK) cells in two cancer clinical trials. In August 2023, the company announced FDA clearance for an IND for lupus – marking a first for an al...
Our guest on the podcast this week is John Cassidy, director of life sciences and healthtech investments at SoftBank Vision Fund.Softbank Vision Fund is the world’s largest technology-focused investment fund, with $166bn assets under management, and a portfolio of more than 250 companies.In the discussion, we cover investment trends within life sciences, the European health and biotech scene, as well as the precise applications of new and emerging AI technologies. We also look ahead to what t...
There is a constant risk of severe, potentially life-threatening allergic reactions for individuals with peanut allergies, which leads to significant physical, social, and emotional burdens.IgGenix, a clinical-stage immunology biotechnology company, recently announced the first patient dosed in its phase 1 trial evaluating IGNX001, a novel monoclonal antibody-based therapeutic, for peanut allergy. Designed to neutralize the most clinically important peanut allergens and epitopes, IGNX001...
ambiom is a life science commercial-advisory business development company based in the Slovakian capital of Bratislava.The company helps its corporate clients with their product strategy, in- and out-licensing efforts, including asset valuation (NPV, rNPV), M&A scouting, complex due diligence and dealmaking.ambiom also provides input on regulatory matters, support in pricing and reimbursement decisions and communication with decision-making authorities. The company guides products from th...
Biological control company Oxitec recently launched Sparks, a new platform designed to rapidly scale Wolbachia replacement technology to take on dengue fever.Backed by a multi-million-dollar investment from the Gates Foundation, Sparks adds to Oxitec’s Aedes aegypti technology, called Friendly, which is taking on dengue fever in Brazil. With mosquito-borne diseases on the rise, Oxitec’s Friendly mosquitoes are designed to suppress populations of disease-spreading mosquitoes and, in turn,...
Immunology is a key area in biotech and biopharma, both in terms of R&D and sales.However, according to UK-headquartered Greywolf Therapeutics, the industry has only focused on two-thirds of the puzzle.To have an immunological effect, you must activate the body’s T cells, which cells requires a chain of three key signals. The first is antigen recognition, i.e. the initial detection of a cell by a T-cell. The second is the co-stimulation of non-antigen presenting molecules, which enhances ...
The Bill & Melinda Gates Medical Research Institute (Gates MRI) is a non-profit medical research organization dedicated to the development and effective use of products like drugs, vaccines and monoclonal antibodies to address substantial global health concerns, for which investment incentives are limited, including malaria, tuberculosis, diarrheal diseases, and diseases that impact maternal, newborn, and child health.This week, our guest is Dr Claire Wagner, head of corporate strategy an...
This week, we are taking a look at an important subject, and that is women working as CEOs, or other senior roles, in the biotech space. Kate Yen is the CEO of oncology biotech Auron Therapeutics, and she has spent her entire career in science. Auron is working on the next generation of targeted cancer therapies by identifying and inhibiting the oncogenic cell states of cancer. Auron’s AURIGIN platform uses AI and machine learning to compare normal cell states with cancerous cell st...
Sitryx Therapeutics is a private UK biopharma company founded in 2018. It is a leader in the field of immunometabolism, an area of immunology that looks to rebalance the immune system to achieve sustained disease remission in autoimmune and inflammatory diseases. Sitryx already has big pharma validation following a deal with Eli Lilly in 2020 worth in excess of $1 billion and is focused on advancing its pipeline of potentially first- and best-in-class therapies, which could address a wid...
1LinkGevity, founded by two sisters, is developing anti-necrotic technologies, especially for application in kidney disease.Carina Kern is the CEO of the company, while Serena Kern-Libera is the chief operating officer. After reading an article about how space-travel is especially damaging to the kidneys, they applied for a place on the inaugural NASA Space-H Accelerator program, and how medicine can support human deep-space missions.LinkGevity was selected for the program, which is in its ina...
Today, gene therapy is at an exciting inflection point as the industry moves beyond the first generation of these therapies. However, challenges and barriers remain in bringing gene therapies to market, particularly as they expand into more prevalent diseases. Spur Therapeutics is a clinical-stage biotech company dedicated to developing next generation gene therapies for people living with chronic, debilitating diseases. Its lead candidate, FLT201, is an AAV gene therapy for Gaucher...
Antibody-drug conjugates have been an area of great interest in the oncology space in recent years, with a record rate of FDA approvals and dealmaking activity. However balancing efficacy and off-site toxicity has remained a challenge.Some biopharma companies are investing in what they hope will be the next-generation approach to ADCs – bispecific ADCs. More than a dozen early-stage clinical trials are evaluating whether adding a second targeting functionality can improve the preciseness...
Telomeres are structures made from DNA sequences and proteins, and they are found at the ends of chromosomes. In effect, they cap and protect the end of a chromosome. Telomerase is an enzyme that adds DNA to the ends of chromosomes, and it is reactivated in most cancers. Most human tumors not only express telomerase but also have very short telomeres. This makes telomerase a prime target for cancer therapies. MAIA Biotechnology is focused on the pioneering approach of telomere targeting ...
C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. The clinical-stage biopharmaceutical company is dedicated to creating a new generation of medicines using its TORPEDO platform to design and optimize small-molecule medicines to address difficult-to-treat diseases. TORPEDO can design molecular glues and heterobifunction...
Estonia is working on becoming the first country to implement personalized health at scale through the Estonian National Biobank.The biobank uses genetic data to create a picture of the Estonian population, leading to the potential adaptation of public health systems. The Estonian Biobank has samples from 20% of the adult population; in comparison, UK biobanks only represent 0.7% of the population. With so much data, Estonia can determine risk factors for cancer, cardiovascular disease, ...
Inflammation appears to affect almost every part of the human body as we age, including cancer, type-2 diabetes, obesity, and neurodegenerative disorders.NLRP3 inflammasome-induced inflammation is at the root of nearly all disease pathologies including fibrotic, dermatological, rheumatological diseases as well as neurological disorders such as Alzheimer’s disease.Halia Therapeutics is a clinical-stage biopharmaceutical company pioneering a novel class of small molecule medications designed to...
Tumor infiltrating lymphocyte (TIL) therapy uses a person’s own immune cells to fight advanced melanoma, offering new hope for patients who have limited treatment options. This week, we have a conversation with Brian Gastman, EVP of medical affairs at Iovance Biotherapeutics, about TILs and the company’s pipeline.Iovance recently submitted a marketing authorization application to the European Medicines Agency for lifileucel, a TIL cell therapy, for the treatment of adult patients with un...
The development of combination vaccines could represent a significant advancement in the fight against infectious diseases. With the potential to streamline the vaccination process and provide broader protection, these vaccines could greatly improve public health preparedness.Moderna is harnessing the power of its mRNA platform to develop vaccines that target multiple respiratory viruses at once, including COVID-19, RSV, and influenza. The breakthrough technology enables the immune system to ...
Pentixapharm is a clinical-stage radiopharmaceutical development company targeting a range of diseases. While it is currently owned by the Eckert & Ziegler Group, it will soon be spun off as a separate company. Pentixapharm’s clinical pipeline includes PENTIXATHER, am Yttrium-90 based therapeutic against CNS lymphoma, and PENTIXAFOR, a Gallium-68 based companion diagnostic. Additionally, PENTIXAFOR is being developed as a diagnostic tool for primary aldosteronism (PA), a significant ...
There are many questions when it comes to setting up a biotech company, and raising funds. Currently, many companies are concerned about fundraising, but there are things that can be done to maximize efforts. Does a company’s location affect fundraising? What is the best approach to successfully raise funds? What are the current trends in biotech funding?To look at questions surrounding the state of European biotech funding, and how it compares with the global scene, intellectual property, an...
Comments
Top Podcasts
The Best New Comedy Podcast Right Now – June 2024The Best News Podcast Right Now – June 2024The Best New Business Podcast Right Now – June 2024The Best New Sports Podcast Right Now – June 2024The Best New True Crime Podcast Right Now – June 2024The Best New Joe Rogan Experience Podcast Right Now – June 20The Best New Dan Bongino Show Podcast Right Now – June 20The Best New Mark Levin Podcast – June 2024
Download from Google Play
Download from App Store
United States